Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland coronary prevention study

Circulation

Volumn 103, Issue 3, 2001, Pages 357-362

  Freeman, Dilys J ^a   Norrie, John ^b   Sattar, Naveed ^c   Neely, R Dermot G ^d   Cobbe, Stuart M ^e   Ford, Ian ^b   Isles, Christopher ^f   Lorimer, A Ross ^e   Macfarlane, Peter W ^e   McKillop, James H ^e   Packard, Christopher J ^c   Shepherd, James ^c   Gaw, Allan ^c  

^a DURHAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^d UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

^f DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

Author keywords

Diabetes mellitus; Lipids; Prevention; Risk factors; Trials

Indexed keywords

GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIABETOGENESIS; DRUG EFFECT; ENDOTHELIUM; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

EID: 0035936527     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.3.357     Document Type: Article

References (30)

1. Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: The Framingham Study
2. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance
3. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance
4. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study); a cohort study
5. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary disease start ticking before the onset of clinical diabetes?
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels
9. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
10. Effect of pravastatin on outcomes after cardiac transplantation
11. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial
12. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
13. Screening experience and baseline characteristics in the West of Scotland Study
14. Lipid Research Clinics Program
15. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction
16. Protection from obesity-induced insulin resistance in mice lacking TNF-α function
17. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance
18. Is leptin the link between obesity and insulin resistance?
19. Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hyper-cholesterolemia
20. Effects of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on glucose tolerance in patients with essential hypertension
21. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in non-diabetic subjects with mild hypertriglyceridemia
22. Inhibition of proinflammatory cytokine production by pravastatin
23. Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells
24. Effects of endotoxins and cytokines on lipid metabolism
25. Hemodynamie changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin
26. Pravastatin has cholesterol-lowering independent effects on the artery wall of athero-sclerotic monkeys
27. Beneficial effect of cholesterol lowering therapy on coronary endothelium-dependent relaxation in hypereholes-terolaemic patients
28. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects
29. The design of a prospective study of pravastatin in the elderly at risk (PROSPER)